Study of VVN001 Ophthalmic Solution in Dry Eye Disease

VivaVision Biotech

Status and phase: Completed; Phase 2

Conditions: Dry Eye

Treatments: Drug: VVN001 Ophthalmic Solution 5%; Drug: Vehicle; Drug: VVN001 Ophthalmic Solution 1%

Study type: Interventional

Funder types: Industry

Identifiers

NCT04556838

VVN001-CS-201

Details and patient eligibility

About

This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and tolerability and to explore the efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease.

Enrollment: 169 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provide written informed consent prior to any study-related procedures .
• Are 18 years of age or older.
• Are willing and able to follow instructions and willing to be present for the required study visits for the duration of the study.
• Have a best corrected visual acuity (BCVA), using corrective lenses if necessary, in the qualifying eye(s) of +0.7 or better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) at the screening visit and randomization visit.
• Have a history of dry eye disease in both eyes
• Are currently using artificial tears and have been using within 30 days of the screening visit.
• Have an Eye dryness score ≥40 at Visit 1 and ≥35 at Visit 2, one score for both eyes (0-100 point VAS)
• Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2:
• Inferior CFS (iCFS) score of ≥2 (NEI; 0-4 scale; using 0.5 unit increments)
• Have a Schirmer score (without anesthesia) of ≥1 and ≤7 mm/5 min.

Exclusion criteria

• Have a known hypersensitivity or contraindication to the IP or components of IP.
• Have a Schirmer score (without anesthesia) of <1 or >7 mm/5 min in the study eye.
• Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

169 participants in 3 patient groups, including a placebo group

VVN001, 1%

Experimental group

Description:

VVN001, 1% ophthalmic solution

Treatment:

Drug: VVN001 Ophthalmic Solution 1%

VVN001, 5%

Experimental group

Description:

VVN001, 5% ophthalmic solution

Treatment:

Drug: VVN001 Ophthalmic Solution 5%

Vehicle

Placebo Comparator group

Description:

VVN001 Ophthalmic Solution Placebo

Treatment:

Drug: Vehicle